FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications
On March 1, 2024, the Food and Drug Administration approved amivantamab-vmjw with carboplatin and pemetrexed…
On March 1, 2024, the Food and Drug Administration approved amivantamab-vmjw with carboplatin and pemetrexed…
Lung cancer ranks second among the most common cancers worldwide and is the leading cause…
A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune…
A new study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center shows that using…
The Janssen Pharmaceutical Companies of Johnston & Johnson announced the submission of a marketing authorisation application…
Researchers at the Icahn School of Medicine at Mount Sinai, USA, have identified an allergy…
For patients with advanced or metastatic non-small cell lung cancer (NSCLC) and limited performance status,…
The largest review of papers for brain cancer that has spread from the lungs has…
For patients with advanced or metastatic non-small cell lung cancer (NSCLC) and limited performance status,…
November is Lung Cancer Awareness Month and as the fourth most diagnosed cancer and the…